SOLV Stock Overview
A healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 3/6 |
| Past Performance | 1/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Solventum Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$67.62 |
| 52 Week High | US$85.92 |
| 52 Week Low | US$47.16 |
| Beta | 0 |
| 1 Month Change | -11.75% |
| 3 Month Change | -8.70% |
| 1 Year Change | 4.59% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.48% |
Recent News & Updates
New VAC Product And AI Will Simplify Procedures
Mar 30 Streamlining operations and divesting non-core assets are expected to improve margins, reduce leverage, and focus growth efforts on core segments.Is Solventum (NYSE:SOLV) Using Too Much Debt?
Mar 28
Recent updates
New VAC Product And AI Will Simplify Procedures
Mar 30 Streamlining operations and divesting non-core assets are expected to improve margins, reduce leverage, and focus growth efforts on core segments.Is Solventum (NYSE:SOLV) Using Too Much Debt?
Mar 28Solventum: An Impressive Sale Of Purification And Filtration
Feb 26Solventum Corporation's (NYSE:SOLV) Intrinsic Value Is Potentially 32% Above Its Share Price
Feb 02These 4 Measures Indicate That Solventum (NYSE:SOLV) Is Using Debt Extensively
Dec 11Solventum: Concerns After A Partial Re-Rating
Nov 30A Look At The Intrinsic Value Of Solventum Corporation (NYSE:SOLV)
Oct 10Solventum: No Rush To Buy As Post-Spin Execution Will Take Time To Play Out
Sep 11Solventum (NYSE:SOLV) Has A Pretty Healthy Balance Sheet
Aug 18Solventum: Stumbling Out Of The Gate
Jul 07Solventum Corporation (NYSE:SOLV) Shares Could Be 27% Below Their Intrinsic Value Estimate
Jun 26Solventum: A Reasonable Start, Still Some Questions To Be Asked
May 173M Says Bye To Solventum - Why I Stick To My Bullish Call
Apr 02Shareholder Returns
| SOLV | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 2.3% | 1.5% | 2.9% |
| 1Y | 4.6% | 8.3% | 10.0% |
Return vs Industry: SOLV underperformed the US Medical Equipment industry which returned 6.3% over the past year.
Return vs Market: SOLV underperformed the US Market which returned 9.5% over the past year.
Price Volatility
| SOLV volatility | |
|---|---|
| SOLV Average Weekly Movement | 6.2% |
| Medical Equipment Industry Average Movement | 9.2% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: SOLV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SOLV's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2023 | 22,000 | Bryan Hanson | www.solventum.com |
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates in four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers solutions for negative pressure wound therapy, advanced wound dressings, advanced skin care, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wrap, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers.
Solventum Corporation Fundamentals Summary
| SOLV fundamental statistics | |
|---|---|
| Market cap | US$11.35b |
| Earnings (TTM) | US$479.00m |
| Revenue (TTM) | US$8.25b |
24.4x
P/E Ratio1.4x
P/S RatioIs SOLV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOLV income statement (TTM) | |
|---|---|
| Revenue | US$8.25b |
| Cost of Revenue | US$3.64b |
| Gross Profit | US$4.61b |
| Other Expenses | US$4.13b |
| Earnings | US$479.00m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 08, 2025
| Earnings per share (EPS) | 2.77 |
| Gross Margin | 55.88% |
| Net Profit Margin | 5.80% |
| Debt/Equity Ratio | 270.7% |
How did SOLV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/02 04:48 |
| End of Day Share Price | 2025/05/02 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Solventum Corporation is covered by 14 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Travis Steed | BofA Global Research |
| Travis Steed | BofA Global Research |
| Michael Gorman | BTIG |